Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL13622863 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL15590870 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL759366 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL12929005 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18389589 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL10122072 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13241436 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3531 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324968-B1 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER | ATHENEX THERAPEUTICS LTD (CN) | 2023-09-27 | — | — | EP | claimed |
| WO-2023141560-A2 | ALKALINE PHOSPHATASE FOR USE IN ONCOLOGY | SYNTHETIC BIOLOGICS, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| CN-115317451-A | Cel-CSO/Taxol NPs nano-medicine and application thereof | 河南中医药大学 | 2022-11-11 | — | — | CN | claimed |
| US-20220298252-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | PELICAN THERAPEUTICS, INC. | 2022-09-22 | — | — | US | claimed |
| EP-4021494-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | Pelican Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220185863-A1 | COMBINATION THERAPIES | SHATTUCK LABS, INC. | 2022-06-16 | — | — | US | claimed |
| CN-114502195-A | Methods of treating cancer using TNFRSF25 antibodies | 派立卡恩治疗公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3930851-A1 | COMBINATION THERAPIES | Shattuck Labs, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113747947-A | Combination therapy | 沙塔克实验室有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-101961484-A | Prostate secretory protein 94/57 (Psp94/57), analogous polypeptides thereof for preparing medicaments for eliminating drug (therapy) resistance of tumor, and application thereof | LIU JINLONG | 2011-02-02 | — | — | CN | claimed |
| US-20100330147-A1 | Drug Delivery Compositions Including Nanoshells For Triggered Drug Release | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2010-12-30 | — | — | US | claimed |
| CN-101785880-A | Blood vessel bracket utilizing titanium oxide nanotube to load medicine | UNIV SOUTHEAST | 2010-07-28 | — | — | CN | claimed |
| US-7714139-B2 | IDO inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDCIAL RESEARCH (US) | 2010-05-11 | — | — | US | claimed |
| CN-100490850-C | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN NINGBO YINGNUO PHARMACE (CN) | 2009-05-27 | — | — | CN | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| EP-1159974-B1 | Anti-angiogenic compositions containing taxol and a non-biodegradable carrier and their use | ANGIOTECH PHARM INC (CA) | 2007-07-18 | — | — | EP | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-1557507-A | Re-stricture preventing medicinal sustained releasing bracket and its preparation | 东南大学 | 2004-12-29 | — | — | CN | claimed |